Effect of low molecular weight fucoidan and low molecular weight heparin in a rabbit model of arterial thrombosis

Journal of Vascular Research

Volumn 45, Issue 6, 2008, Pages 529-537

  Durand, Eric ^a,b,c   Helley, Dominique ^a,b,c   Al Haj Zen, Ayman ^a,b   Dujols, Céline ^b   Bruneval, Patrick ^a,b,c   Colliec Jouault, Sylvia ^d   Fischer, Anne Marie ^a,b,c   Lafont, Antoine ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d IFREMER   (France)

Author keywords

Fucoidan; Heparin; Thrombosis; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

ENOXAPARIN; FUCOIDIN; LOW MOLECULAR WEIGHT HEPARIN; STAUROSPORINE; THROMBOPLASTIN;

ANIMAL MODEL; APOPTOSIS; ARTERY THROMBOSIS; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DRUG EFFECT; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOCYTE AGGREGATION;

ANIMALS; APOPTOSIS; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMORAL ARTERY; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; LIPOPROTEINS; MALE; PLATELET AGGREGATION; POLYSACCHARIDES; RABBITS; STAUROSPORINE; THROMBOPLASTIN; THROMBOSIS;

EID: 54249089324     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000129687     Document Type: Article

References (26)

1. Nardella A, Chaubet F, Boisson-Vidal C, Blondin C, Durand P, Josefonvicz J: Anticoagulant low molecular weight fucans produced by radical process and ion exchange chromatography of high molecular weight fucans extracted from the brown seaweed Ascophyllum nodosum. Carbohydr Res 1996;289:201-208.
2. Mauray S, Sternberg C, Theveniaux J, Millet J, Sinquin C, Tapon-Bretaudiere J, Fischer AM: Venous antithrombotic and anticoagulant activities of a fucoidan fraction. Thromb Haemost 1995;74:1280-1285.
3. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP: Cultured normal hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principle site of its synthesis. Proc Natl Acad Sci USA 1990;87:8869-8873.
4. Lupu C, Poulsen E, Roquefeuil S, Westmuckett AD, Kakkar VV, Lupu F: Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1999;19:2251-2262.
5. Giraux JL, Tapon-Bretaudiere J, Matou S, Fischer AM: Fucoidan, as heparin, induces tissue factor pathway inhibitor release from cultured human endothelial cells. Thromb Haemost 1998;80:692-695.
6. Millet J, Colliec Jouault S, Mauray S, Theveniaux J, Sternberg C, Boisson Vidal C, Fischer AM: Antithrombotic and anticoagulant activities of a low molecular weight fucoidan by the subcutaneous route. Thromb Haemost 1999;81:391-395.
7. Colliec-Jouault S, Durand P, Fischer AM: Low molecular weight sulphated polysaccharide to obtain a medicine with antithrombotic activity. United States Patent No. 6,828,307, 2004.
8. Durand E, Scoazec A, Lafont A, Al Haj Zen A, Addad F, Mirshahi M, Desnos M, Tedgui A, Mallat Z: In vivo induction of endothelial apoptosis leads to vessel thrombosis and endothelial denudation. Circulation 2004;109:2503-2506.
9. D'Andrea D, Ravera M, Golino P, Rosica A, De Felice M, Ragni M, Cirillo P, Vigorito F, Corcione N, Tommasini P, Gargiulo A, Piro O, Calabro P, Chiariello M: Induction of tissue factor in the arterial wall during recurrent thrombus formation. Arterioscler Thromb Vasc Biol 2003;23:1684-1689.
10. Carter CJ, Kelton JG, Hirsh J: Comparison of haemorrhagic effect of porcine and bovine heparin in the rabbits. Thromb Res 1979;15:581-586.
11. Doutremepuich C, Toulemonde F, Bousquet F, Bonini F: Comparison of haemorrhagic effect of unfractionated heparin and a low molecular weight heparin fraction (CY 216) in rabbits. Thromb Res 1986;43:691-695.
12. Sandset PM, Warn-Cramer BJ, Rao VM, Maki SL, Rapaport SI: Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminate intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA 1991;88:708-712.
13. Cohen M: The role of low molecular weight heparin in the management of acute coronary syndromes. J Am Coll Cardiol 2003;41(suppl S):55S-61S.
14. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y: Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999;96:2311-2315.
15. Tedgui A, Mallat Z: Apoptosis as a determinant of atherothrombosis. Thromb Haemost 2001;86:420-426.
16. Moons AH, Levi M, Peters RJ: Tissue factor and coronary artery disease. Cardiovasc Res 2002;53:313-325.
17. Ragni M, Golino P, Cirillo P, Scognamiglio A, Piro O, Esposito N, Battaglia C, Botticella F, Ponticelli P, Ramunno L, Chiariello M: Endogenous tissue factor pathway inhibitor modulates thrombus formation in an in vivo model of rabbit carotid artery stenosis and endothelial injury. Circulation 2000;102:113-117.
18. Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Juhan-Vague I, PRIME study group: Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 2004;109:1343-1348.
19. Sundaram M, Qi Y, Shriver Z, Liu D, Zhao G, Venkataraman G, Langer R, Sasisekharan R: Rational design of low molecular weight heparins with improved in vivo activity. Proc Natl Acad Sci USA 2003;100:651-656.
20. Thorlacius H, Vollmar B, Seyfert UT, Vestweber D, Menger MD: The polysaccharide fucoidan inhibits microvascular thrombus formation independently from P- and L-selectin function in vivo. Eur J Clin Invest 2000;30:804-810.
21. Chabut D, Fischer AM, Colliec-Jouault S, Laurendeau I, Matou S, Le Bonniec B, Helley D: Low molecular weight fucoidan and heparin enhance the FGF-2 induced tube formation of endothelial cells through heparan sulfate-dependent alpha 6 over-expression. Mol Pharmacol 2003;64:696-702.
22. Logeart D, Prigent-Richard S, Jozefonvicz J, Letourneur D: Fucans, sulfated polysaccharides extracted from brown seaweeds, inhibit vascular smooth muscle cell proliferation. 1. Comparison with heparin for antiproliferative activity, binding and internalization. Eur J Cell Biol 1997;74:376-384.
23. Logeart D, Prigent-Richard S, Boisson-Vidal C, Chaubet F, Durand P, Jozefonvicz J, Letourneur D: Fucans, sulfated polysaccharides extracted from brown seaweeds, inhibit vascular smooth muscle cell proliferation. 2. Degradation and molecular weight effect. Eur J Cell Biol 1997;74:385-390.
24. Deux JF, Meddahi-Pelle A, Le Blanche AF, Feldman LJ, Colliec-Jouault S, Bree F, Boudghene F, Michel JB, Letourneur D: Low molecular weight fucoidan prevents neointimal hyperplasia in rabbit iliac artery in-stent restenosis model. Arterioscler Thromb Vasc Biol 2002;22:1604-1609.
25. Luyt CE, Meddahi-Pelle A, Ho-Tin-Noe B, Colliec-Jouault S, Guezennec J, Louedec L, Prats H, Jacob MP, Osborne-Pellegrin M, Letourneur D, Michel JB: Low molecular weight fucoidan promotes therapeutic revascularization in a rat model of critical hindlimb ischemia. J Pharmacol Exp Ther 2003;305:24-30.
26. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM: Lessons from sudden coronary death: a comprehensive morphological classification scheme for athero-sclerotic lesions. Arterioscler Thromb Vasc Biol 2000;20:1262-1275.